Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022GlobeNewsWire • 01/06/22
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022GlobeNewsWire • 01/05/22
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune DiseasesGlobeNewsWire • 01/05/22
Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In HumansSeeking Alpha • 12/15/21
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaGlobeNewsWire • 12/13/21
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)GlobeNewsWire • 11/22/21
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/05/21
Intellia Therapeutics, Inc. (NTLA) CEO Dr. John Leonard on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 11/04/21
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21